Citation: Dr. Budman et al., In vitro effects of dexrazoxane (Zinecard) and classical acute leukemia therapy: time to consider expanded clinical trials?, LEUKEMIA, 15(10), 2001, pp. 1517-1520
Authors:
Budman, DR
Johnson, R
Barile, B
Bowsher, RR
Vinciguerra, V
Allen, SL
Kolitz, J
Ernest, CS
Kreis, W
Zervos, P
Walling, J
Citation: Dr. Budman et al., Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesis, CANC CHEMOT, 47(6), 2001, pp. 525-531
Citation: W. Kreis et al., A reexamination of PSC 833 (Valspodar) as a cytotoxic agent and in combination with anticancer agents, CANC CHEMOT, 47(1), 2001, pp. 78-82
Authors:
Liu, XM
Wang, LG
Kreis, W
Budman, DR
Adams, LM
Citation: Xm. Liu et al., Differential effect of vinorelbine versus paclitaxel on ERK2 kinase activity during apoptosis in MCF-7 cells, BR J CANC, 85(9), 2001, pp. 1403-1411
Authors:
Hornberger, M
Bottigheimer, U
Hillier-Kaiser, A
Kreis, W
Citation: M. Hornberger et al., Purification and characterisation of the cardenolide-specific beta-glucohydrolase CGH II from Digitalis lanata leaves, PL PHYS BIO, 38(12), 2000, pp. 929-936
Citation: W. Kreis et al., Purification and characterization of a polyphenol oxidase from the herbal drug Echinaceae purpureae herba (Purple cone flower herb), J APPL BOT, 74(3-4), 2000, pp. 106-112
Citation: B. Nusslein et W. Kreis, Purification of cynaroside 7-O-beta-D-glucosidase from the herbal drug Cynarae folium (artichoke leaves), J APPL BOT, 74(3-4), 2000, pp. 113-118
Authors:
Kasimis, B
Wilding, G
Kreis, W
Feuerman, M
Chang, V
Hwang, S
Steafather, H
Cogswell, J
Rae, C
Blumenfrucht, M
Citation: B. Kasimis et al., Survival of patients who had salvage castration after failure on bicalutamide monotherapy for stage (D-2) prostate cancer, CANCER INV, 18(7), 2000, pp. 602-608
Authors:
Terada, Y
Misoi, R
Watanabe, N
Hornberger, M
Kreis, W
Citation: Y. Terada et al., Structure-specificity relationship of cardiac glycosides as a substrate for glucohydrolase II, CHEM PHARM, 48(3), 2000, pp. 349-352
Authors:
Kreis, W
Budman, DR
Fetten, J
Gonzales, AL
Barile, B
Vinciguerra, V
Citation: W. Kreis et al., Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma, ANN ONCOL, 10(1), 1999, pp. 33-38
Citation: Lg. Wang et al., The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review, CANC CHEMOT, 44(5), 1999, pp. 355-361
Citation: W. Kreis et D. Budman, Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer, SEMIN ONCOL, 26(5), 1999, pp. 34-38
Authors:
Savarese, D
Taplin, ME
Halabi, S
Hars, V
Kreis, W
Vogelzang, N
Citation: D. Savarese et al., A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: Preliminary results of cancer and leukemia group B trial 9780, SEMIN ONCOL, 26(5), 1999, pp. 39-44
Citation: Lg. Wang et al., Synergistic effect of estramustine and [3 '-keto-Bmtl](Val2]-cyclosporine (PSC 833) on the inhibition of androgen receptor phosphorylation in LNCaP cells, BIOCH PHARM, 58(7), 1999, pp. 1115-1121
Citation: Lg. Wang et al., Phosphorylation dephosphorylation of androgen receptor as a determinant ofandrogen agonistic or antagonistic activity, BIOC BIOP R, 259(1), 1999, pp. 21-28
Citation: C. Theurer et al., Effects of digitoxigenin, digoxigenin, and various cardiac glycosides on cardenolide accumulation in shoot cultures of Digitalis lanata, PLANTA MED, 64(8), 1998, pp. 705-710